Hepatic tumor growth: Target for angiogenesis inhibition?

World Journal of Surgery

Volumn 29, Issue 3, 2005, Pages 287-292

  Sarraf Yazdi, Shiva ^a   Mi, Jing ^a   Clary, Bryan M ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; BEVACIZUMAB; VASCULOTROPIN;

ANGIOGENESIS; CANCER CHEMOTHERAPY; CELL SURVIVAL; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONFERENCE PAPER; DEATH; GENE TARGETING; HUMAN; LIVER METASTASIS; NONHUMAN;

ANGIOGENESIS INHIBITORS; ANGIOPOIETINS; ANTIBODIES, MONOCLONAL; COLORECTAL NEOPLASMS; HUMANS; LIVER NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTOR, TIE-2;

EID: 20044370306     PISSN: 03642313     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00268-004-7810-9     Document Type: Conference Paper

References (95)

1. J Folkman 1995 Clinical applications of research on angiogenesis N. Engl. J. Med. 333 1757
2. P Carmeliet RK Jain 2000 Angiogenesis in cancer and other diseases Nature 407 249
3. CR Berney RJ Fisher J-L Yang 1999 Protein markers in colorectal cancer: predictors of liver metastasis Ann. Surg. 230 179
4. C Barozzi M Ravaioli A D'Errico 2002 Relevance of biologic markers in colorectal carcinoma: a comparative study of a broad panel Cancer 94 647
5. A Vonlaufen G Wiedle B Borisch 2001 Integrin alpha (v) beta (3) expression in colon carcinoma correlates with survival Modern Patholo. 14 1126
6. M Haraguchi K Komuta A Akashi 2002 Elevated IL-8 levels in the drainage vein of resectable Dukes' C colorectal cancer indicate high risk for developing hepatic metastasis Oncol. Rep. 9 159
7. P Vermeulen G Van den Eynden P Huget 1999 Prospective study of uitratumoral microvessel density, p53 expression and survival in colorectal cancer Br. J. Cancer 79 316
8. M Davies J Kaur T Allen-Mersh 2000 Plasma vascular endothelial but not fibroblast growth factor levels correlate with colorectal liver metastasis vascularity and volume Br. J. Cancer 82 1004
9. ML Rothenberg DP Carbone DH Johnson 2003 Improvuig challenges and opportunities Nat. Rev. Cancer 3 303
10. R Kerbel 2001 Clinical trials of antiangiogenic drugs: opportunities, problems, and assessment of initial results J. Clin. Oncol. 19 45s
11. Hurwitz, H, Fehrenbacher L, Cartwright et al. Bevacizumab (Avastin, a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): results of a phase III trial of Bevacizumab in combination with bolus IFL (Irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC. Proceedings of the American Society of Clinical Oncology. Abstract No. 3646, 2003
12. S Ahmad R Berman LM Ellis 2003 Biology of colorectal liver metastases Surg. Oncol. Clin. North Am. 12 135
13. J Folkman 1990 What is the evidence that tumors are angiogenesis dependent? J Natl. Cancer Inst. 82 4
14. LA Liotta WG Stetler-Stevenson 1990 Tumor invasion and metastasis: an imbalance of positive and negative regulation Cancer Res 51 504
15. M Papetti IM Herman 2002 Mechanisms of normal and tumor-derived angiogenesis Am. J. Physiol. Cell Physiol. 282 C947
16. C Kuo F Farnebo E Yu 2001 Comparative evaluation of antitumor activity of antiangiogenic proteins delivered by gene transfer Proc. Natl. Acad. Sci. USA 98 4605
17. G Siemeistery M Schirner K Weindel 1999 Two independent mechanisms essential for tumor angiogenesis: inhibition of human melanoma xenograft growth by interfering with either the vascular endothelial growth factor receptor pathway or the Tie-2 pathway Cancer Res. 59 3185
18. O Stoeltzing SA Ahmad L Wenbiao 2003 Angiopoietin-1 inhibits vascular permeability, angiogenesis, and growth of hepatic colon cancer tumors Cancer Res. 63 3370
19. P Gervaz B Scholl V Padrum 2000 Growth inhibition of liver metastases by the anti-angiogenic drug TNP-470 Liver 20 108
20. J Watson E Sutanto-Ward M Osaku 1999 Importance of timing and length of administration of angiogenesis inhibitor TNP-470 in the treatment o fK12/TRb colorectal hepatic metastases in BD-IX rats Surgery 126 358
21. K Murakami R Sakukawa M Sano 1999 Inhibition of angiogenesis and intrahepatic growth of colon cancer by TAC-101 Clin. Cancer Res. 5 2304
22. R Shaheen W Tseng D Davis 2001 Tyrosine kinase inhibition of multiple angiogenic growth factor receptors improves survival in mice bearing colon cancer liver metastases by inhibition of endothelial cell survival mechanisms Cancer Res. 61 1464
23. LM Ellis Y Takahashi W Liu 2000 Vascular endothelial growth factor in human colon cancer: biology and therapeutic implications Oncologist 5 11
24. P Pavco K Bouhana A Gallegos 2000 Antitumor and antimetastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptors Clin. Cancer Res. 6 2094
25. H Yoshiji S Kuriyama D Hicklin 1999 KDR/Flk-1 is a major regulator of vascular endothelial growth factor-induced tumor development and angiogenesis in murine hepatocellular carcinoma cells Hepatology 30 1179
26. HL Kong D Hecht W Song 1998 Regional suppression of tumor growth by in vivo transfer of a cDNA encoding a secreted form of the extracellular domain of the flt-1 vascular endothelial growth factor receptor Hum. Gen. Ther. 9 823
27. H Konno T Arai T Tanaka 1998 Antitumor effect of a neutralizing antibody to vascular endothelial growth factor on liver metastasis of endocrine neoplasm Jpn. J Cancer Res. 89 933
28. C Bruns W Liu D Davis 2000 Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases Cancer 89 488
29. J Huang J Moore S Soffer 2001 Highly specific antiangiogenic therapy is effective in suppressing growth of experimental Wilms tumors J. Pediatr. Surg. 36 357
30. ES Kim A Serur J Huang 2002 Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma Proc. Natl. Acad. Sci. USA 99 11399
31. S Yoon H Eto C Lin 1999 Mouse endostatin inhibits the formation of lung and liver metastases Cancer Res. 59 6251
32. TA Drixler IHMB Rinkes ED Ritchie 2000 Continuous administration of angiostatin inhibits accelerated growth of colorectal liver metastases after partial hepatectomy Cancer Res 60 1761
33. MS O'Reilly L Holmgren Y Shing 1994 Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma Cell 79 315
34. MS O'Reilly T Boehm Y Shing 1997 Endostatin: an endogenous inhibitor of angiogenesis and tumor growth Cell 88 277
35. D Kerr 2003 Clinical development of gene therapy for colorectal cancer Nat. Rev. Cancer 3 615
36. IJ Fidler 2001 Seed and soil revisited: contribution of the organ microenvironment to cancer metastasis Surg. Oncol. Clin. North Am. 10 257
37. S Paget 1889 The distribution of secondary growths in cancer of the breast Lancet 1 99
38. J Ewing 1928 Neoplastic Diseases. A Treatise on Tumors W.B. Saunders Co Philadelphia 77 89
39. AF Chambers AC Groom IC MacDonald 2002 Dissemination and growth of cancer cells in metastatic sites Nat. Rev. Cancer 2 563
40. I Hart IJ Fidler 1980 Role of organ selectivity in the determination of metastatic patterns of B16 melanoma Cancer Res. 41 2281
41. I Hart 1982 "Seed and soil" revisited: mechanisms of site-specific metastasis Cancer Metastasis Rev. 1 5
42. T Fujimaki J Price D Fan 1996 Selective growth of human melanoma cells in the brain parenchyma of nude mice Melanoma Res. 6 363
43. G Poste 1982 Experimental systems for analysis of the malignant phenotype Cancer Metastasis Rev. 1 5
44. D Tarin JE Price MG Kettlewell 1984 Mechanisms of human tumor metastasis studied in patients with peritoneovenous shunts Cancer Res. 44 3584
45. T-H Kuo T Kubota M Watanabe 1995 Liver colonization competence governs colon cancer metastasis Proc. Natl. Acad. Sci. USA 92 12085
46. GK Michalopoulos MC DeFrances 1997 Liver regeneration Science 276 60
47. A Takeda O Stoeltzing SA Ahmad 2002 Role of angiogenesis in the development and growth of liver metastasis Ann. Surg. Oncol. 9 610
48. MA Ross CM Sander TB Kleeb 2001 Spatiotemporal expression of angiogenesis growth factor receptors during the revascularization of regenerating rat liver Hepatology 34 1135
49. TA Drixler MJ Vogten ED Ritchie 2002 Liver regeneration is an angiogenesis-associated phenomenon Ann. Surg. 236 703
50. E Taniguchi S Sakisaka K Matsuo 2001 Expression and role of vascular endothelial growth factor in liver regeneration after partial hepatectomy in rats J. Histochem Cytochem. 49 121
51. TA Drixler IHMB Rinkes ED Ritchie 2000 Continuous administration of angiostatin inhibits accelerated growth of colorectal liver metastases after partial hepatectomy Cancer Res. 60 1761
52. H Uotani I Yamashita T Nagata 2001 Induction of E-selectin after partial hepatectomy promotes metastases to liver in mice J. Surg. Res. 96 197
53. GD Yancopoulos S Davis N Gale 2000 Vascular-specific growth factors and blood vessel formation Nature 407 242
54. DJ Dumont TP Yamaguchi RA Conlon 1992 tek, a novel tyrosine kinase gene located on mouse chromosome 4, is expressed in endothelial cells and their presumptive precursors Oncogene 7 1471
55. T Sato U Tozawa U Deutsch 1995 Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation Nature 376 70
56. D Dumont G Gradwohl G Fong 1994 Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculpgenesis of the embryo Genes Dev 8 1897
57. S Davis TH Aldrich PF Jones 1996 Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning Cell 87 1161
58. A Uemura M Ogawa M Hirashima 2002 Recombinant angiopoietin-1 restores higher-order architecture of growing blood vessels in mice in the absence of mural cells J. Clin. Invest. 110 1619
59. G Thurston C Suri K Smith 1999 Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1 Science 286 2511
60. C Suri P Jones S Patan 1996 Requisite role of angiopoietin-1, a ligand for the Tie2 receptor, during embryonic angiogenesis Cell 87 1171
61. P Maisonpierre C Suri P Jones 1997 Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis Science 277 55
62. AJ Hayes WQ Huang J Yu 2000 Expression and function of angiopoietin-1 in breast cancer Br. J. Cancer 83 1154
63. S Tanaka M Mori Y Sakamoto 1999 Biologic significance of angiopoietin-2 expression in human hepatocellular carcinoma J. Clin. Invest. 103 341
64. SA Ahmad W Liu YD Jung 2001 The effects of angiopoietin-1 and -2 on tumor growth and angiogenesis in human colon cancer Cancer Res. 61 1255
65. J Holash PC Maisonpierre D Compton 1999 Vessel cooption, regression, and growth in rumors mediated by angiopoietins and VEGF Science 284 1994
66. IB Lobov PC Brooks RA. Lang 2002 Angiopoietin-2 displays the VEGF-dependent modulation of capillary structure and endothelial survival in vivo Proc. Natl. Acad. Sci. USA 99 11205
67. T Korff S Kimmina G Martiny-Baron 2001 Blood vessel maturation in a 3-dimensional spheroidal coculture model: direct contact with smooth muscle cells regulates endothelial cell quiescence and abrogates VEGF responsiveness FASEB. J. 15 447
68. RP Visconti CD Richardson TN Sato 2002 Orchestration of angiogenesis and arteriovenous contribution by angiopoietins and vascular endothelial growth factor (VEGF) Proc. Natl. Acad. Sci. USA 99 8219
69. P Lin P Polverini MW Dewhirst 1997 Inhibition of tumor angiogenesis using a soluble receptor establishes a role for Tie2 in pathologic vascular growth J. Clin. Invest. 100 2072
70. P Ln JA Buxton A Acheson 1998 Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2 Proc. Natl. Acad. Sci. USA 95 8829
71. A Stratmann T Acker A Burger 2001 Differential inhibition of tumor angiogenesis by Tie2 and vascular endothelial growth factor receptor-2 dominant-negative receptor mutants Int. J. Cancer. 91 273
72. M Hangai Y Moon N Kitaya 2001 Systemically expressed soluble Tie2 inhibits intraocular neovascularization Human Gene Ther. 12 1311
73. C Contag M. Bachmann 2002 Advances in in vivo bioluminescence imaging of gene expression Ann. Rev. Biomed. Eng. 4 235
74. M Edinger Y-A Cao T Hornig 2001 Advancing animal models of neoplasia through in vivo bioluminescence imaging Eur. J. Cancer 38 2128
75. T Sweeney V Mailander A Tucker 1999 Visualizing the kinetics of tumor-cell clearance in living animals Proc. Natl. Acad. Sci. USA 96 12044
76. M Vooijs J Jonkers S Lyons 2002 Noninvasive imaging of spontaneous retinoblastoma pathway-dependent tumors in mice Cancer Res. 62 1862
77. J Adams M Johnson M Sato 2002 Visualization of advanced human prostate cancer lesions in living mice by a targeted gene transfer vector and optical imaging Nat. Med. 8 891
78. B Laxman D Hall M Bhojani 2002 Noninvasive real-time imaging of apoptosis Proc. Natl. Acad. Sci. USA 99 16551
79. P Ray H Pimenta R Paulmurugan 2002 Noninvasive quantitative imaging of protein-protein interactions in living subjects Proc. Natl. Acad. Sci. USA 99 3105
80. P Ciana M Raviscioni Mussi 2003 imaging of transcriptionally active estrogen receptors Nat. Med. 9 82 86
81. S Ahmad R Berman LM. Ellis 2003 In Vivo Biology of colorectal liver metastases Surg. Oncol. Clin. North Am. 12 135
82. EN Brody L. Gold 2000 Aptamers as therapeutic and diagnostic agents Rev. Mol. Biotechnol. 74 5
83. SE Osborne I Matsumura AD. Ellington 1997 Aptamers as therapeutic and diagnostic reagents: problems and prospects Current Opin. Chem. Biol. 1 5
84. J Floege T Ostendorf U Janssen 1999 Novel approach to specific growth factor inhibition in vivo: Antagonism of platelet-derived growth factor in glomerulonephritis by aptamers Am. J. Pathol. 154 169
85. 165 mediates glomerular endothelial repair J. Clin. Invest. 104 913
86. RR White S Shan C Rusconi 2003 Inhibition of rat corneal angiogenesis by a nuclease-resistant RNA aptamer specific for angiopoietin-2 Proc. Natl. Acad. Sci. USA 100 5028
87. BJ Hicke AW. Stephens 2001 Escort aptamers: a delivery service for diagnosis and therapy J. Clin. Invest. 06 923
88. C Tuerk L. Gold 1990 Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase Science 249 505
89. RR White BA Sullenger CP. Rusconi 2000 Developing aptamers into therapeutics J. Clin. Invest. 106 929
90. WA Pieken DB Olsen F Benseler 1991 Kinetic characterization of ribonuclease-resistant 2'-modified hammer-head ribozymes Science 253 314
91. L Beigelman JA McSwiggen KG Draper 1995 Chemical modification of hammerhead ribozymes. Catalytic activity and nuclease resistance J. Biol. Chem. 270 25705
92. MC Willis B Collins T Zhang 1998 Liposome-anchored vascular endothelial growth factor aptamers Bioconjugate Chem. 9 573
93. BA Sullenger E. Gilboa 2002 Emerging clinical applications of RNA Nature 418 252
94. Q Huang S Shan RD Braun 1999 Noninvasive visualization of tumors in rodent dorsal skin window chambers Nat. Biotechnol. 17 1033
95. C-Y Li S Shan Q Huang 2000 Initial stages of tumor cell-induced angiogenesis: evaluation via skin window chambers in rodent models J. Nat. Cancer Inst. 92 143